{"DataElement":{"publicId":"5832506","version":"1","preferredName":"Person Receive Inhibitor And/Or Inducer Medication Substance Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The indicator to determine patient eligibility for clinical trial participation as outlined in the protocol for questions related to taking inhibitors or inducers.","longName":"5832505v1.0:3506068v1.0","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"5832505","version":"1","preferredName":"Person Receive Inhibition And/Or Induction Medication Substance Clinical Trial Eligibility Criteria","preferredDefinition":"A human being._To take, accept, or get something offered._The interference with or prevention of an action or response even though the stimulus for that action or response is present._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._The act of bringing about something._A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product._Any matter of defined composition that has discrete existence, whose origin may be biological, mineral or chemical._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._A human being._To take, accept, or get something offered._The interference with or prevention of an action or response even though the stimulus for that action or response is present._Used to indicate that either or both of two items or options may be valid._The act of bringing about something._A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product._Any matter of defined composition that has discrete existence, whose origin may be biological, mineral or chemical._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2236731v1.0:5832548v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5832548","version":"1","preferredName":"Receive Inhibition And/Or Induction Medication Substance Clinical Trial Eligibility Criteria","preferredDefinition":"To take, accept, or get something offered.:The interference with or prevention of an action or response even though the stimulus for that action or response is present.:Used to indicate that either or both of two items or options may be valid.:The act of bringing about something.:A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.:Any matter of defined composition that has discrete existence, whose origin may be biological, mineral or chemical.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"5832548v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Inhibition","conceptCode":"C42791","definition":"The interference with or prevention of an action or response even though the stimulus for that action or response is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Induction","conceptCode":"C61367","definition":"The act of bringing about something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Substance","conceptCode":"C45306","definition":"Any matter of defined composition that has discrete existence, whose origin may be biological, mineral or chemical.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FCE1A00-D3D5-5A5B-E053-F662850A2EBA","latestVersionIndicator":"Yes","beginDate":"2017-05-18","endDate":null,"createdBy":"TSESU","dateCreated":"2017-05-18","modifiedBy":"ONEDATA","dateModified":"2017-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FC27AEA-4EC6-13F8-E053-F662850AE372","latestVersionIndicator":"Yes","beginDate":"2017-05-18","endDate":null,"createdBy":"TSESU","dateCreated":"2017-05-18","modifiedBy":"TSESU","dateModified":"2017-05-18","changeDescription":"Created for ABTC-1601 study in Rave per request by J.Zhao. st 5/17/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Has patient received any medi","type":"Preferred Question Text","description":"Has patient received any medications or substances that are strong inhibitors or inducers?","url":null,"context":"ABTC"},{"name":"ABTC-1601 TEXT 1","type":"Alternate Question Text","description":"Has the patient received any strong inhibitors and/or inducers of CYP2C9, CYP2C19, or CYP3A4 (including EIAEDs) in the 10 days prior to the first dose of study drug?","url":null,"context":"ABTC"}],"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FC1F7CC-5A6B-163E-E053-F662850A4EBA","latestVersionIndicator":"Yes","beginDate":"2017-05-18","endDate":null,"createdBy":"TSESU","dateCreated":"2017-05-18","modifiedBy":"TSESU","dateModified":"2017-05-18","changeDescription":"Created for protocol ABTC-1601 per J. Zhao's request. ST 5/17/17.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}